The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|October 16, 2015
That’s Nice and Haig Barrett Launch Consulting Service
Author(s)Pharmaceutical Technology Editors
The two companies will combine life-sciences marketing and a consulting firm to create a life sciences-centered consulting service.
Advertisement
That’s Nice LLC, a research-focused strategic marketing agency for the life-science markets, and Haig Barrett, management consultants based in Los Angeles, announced at CPhI Worldwide 2015 the launch of
“Life Sciences is fast paced and driven by innovation. Communicating the value in an often rapidly-evolving product portfolio is key to success,” said Nigel Walker, Managing Director of That’s Nice, in a press release.
Haig Armaghanian, CEO and founder of Haig Barrett, said, “Life-science companies need creative insight and strategic support in a range of areas. Our integrated services support growth aspirations pursued through mergers and acquisitions, market expansion, or leveraging of the existing customer base through customer experience enhancement and sales enablement.”
Source: That’s Nice
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
Advertisement
Advertisement